London-based Sinclair Pharma enjoys a rise in revenue thanks to demand for of injectable aesthetics
CEO Chris Spooner says that despite competition from bigger firms, ‘what we offer is radically better’
London-based Sinclair Pharma is making solid gains in its transformational year as a pure-play aesthetics company after completing divestment of its medicinal dermatology business in December.
In the first quarter of the year, revenues rose to £8.9 million (HK$84 million) from £7.7 million in the second half of last year. Sinclair’s CEO Chris Spooner attributes the sales growth to robust demand for the company’s highly differentiated portfolio of injectable aesthetics comprising Silhouette, Ellansé, Sculptra and Perfectha.
“We’re competing against companies that are much bigger than us, but what we offer is radically better,” Spooner says. “Today, it’s not necessarily about looking 10 or 15 years younger, but looking beautiful and age-appropriate. To truly address facial ageing, Sinclair is moving beyond filling wrinkles and lines. Our skin lifting and collagen stimulation treatments and next-generation dermal fillers work over time to restore facial shape and volume for a more youthful and natural-looking appearance. This is the subtle way of achieving age-appropriate beauty.”
Sinclair’s top-selling product Silhouette Soft has an excellent track record in terms of efficacy, safety and duration with more than 130,000 procedures performed globally as of June.
Made from polylactic acid, Silhouette Soft is the only non-surgical, minimally invasive treatment that can provide an immediate and natural facelift and long-lasting collagen stimulation, which restores youthful fullness.
In May, the product was launched in the United States under the name Silhouette InstaLift through exclusive distributor ThermiGen.
The only second-generation collagen stimulator that is commercially available, Sinclair’s Ellansé provides immediate volumisation.
Made from polycaprolactone, this fully resorbable injectable filler is available in four duration formulations, lasting from one to four years. Sinclair also reports healthy sales of Sculptra, its first-generation collagen stimulator made of poly-L-lactic acid, and Perfectha, its latest-generation biphasic hyaluronic acid volumising filler for correcting facial wrinkles and contours.
“In terms of technology and approach, we are at the forefront of the injectable aesthetics industry, which is showing great prospects,” Spooner says. “Apart from being fast-growing driven by rising disposable incomes and lifestyle aspirations, the sector provides higher margins and is resilient to economic cycles.”
With an established sales and marketing network in Britain, France, Germany, Italy and Spain, Sinclair is focused on strengthening its foothold in emerging markets through key strategic partners such as Clovers Medical Technology for mainland China, Macau, Hong Kong and Taiwan.
The London Stock Exchange-listed company aims to boost revenues by 40 per cent this calendar year. It sees the US and, over the medium-term, China as areas of significant potential.
http://www.sinclairpharma.com
